LPM Home
Contact LPM





JRGS Home
Aims and Scope
Current Issue
Forthcoming Articles
Archive
Editors




Information For Authors
General Information
Preparation of Manuscripts
How to Submit
Publication Charges
Review Process
Copyright Information

Print Information for Authors
(PDF)


Licence for Users
(PDF)


For Referees


For Librarians

Download
Manuscript Submission Form
.doc, .rtf, .pdf

Publishing Information
Open Access Publishing
Our Publishing Model
Institutional Memberships

Start Your Own Journal

   

Library Publishing Media

  CALL FOR PAPERS
Med J Ad

F
orthcoming
CONFERENCE and EXHIBITION
RNAi2008
c
 
Journal of RNAi and Gene Silencing

 

Journal of RNAi and Gene Silencing (August 2005), 1(1), 26-31

Short Report

Selective cleavage of AChR cRNAs harbouring mutations underlying the slow channel myasthenic syndrome by hammerhead ribozymes

Amr Abdelgany ‡, John Ealing ‡, Matthew Wood † and David Beeson ‡*

ABSTRACT

Slow channel congenital myasthenic syndrome (SCCMS) is a dominant disorder caused by missense mutations in muscle acetylcholine receptors (AChR). Expression from mutant alleles causes prolonged AChR ion-channel activations. This ‘gain of function’ results in excitotoxic damage due to excess entry of calcium ions that manifests as an endplate myopathy. The biology of SCCMS provides a model system to investigate the potential of catalytic nucleic acids for therapy in dominantly inherited disorders involving single missense mutations. Hammerhead ribozymes can catalytically cleave RNA transcripts in a sequence-specific manner. We designed hammerhead ribozymes to target transcripts from four SCCMS mutations, aT254I, aS226F, aS269I and εL221F. Ribozymes were incubated with cRNA transcripts encoding wild type and mutant AChR subunits. The ribozymes efficiently cleaved the mutant allele cRNA transcripts but left the wild type cRNA intact. Cleavage efficiency was optimised for aS226F. We were able to demonstrate robust catalytic activity under simulated physiological conditions and at high Ca2+ concentrations, which is likely to be accumulated at the endplate region of the SCCMS patient muscles. These results demonstrate the potential for gene therapy applications of ribozymes to specifically down-regulate expression of mutant alleles in dominantly inherited disorders.

KEYWORDS: Slow channel myasthenic syndrome, hammerhead ribozymes, AChR, gene therapy, allele-specific mRNA cleavage

‡ Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe Hospital, Oxford OX3 9DS, UK.

† Department of Human Anatomy and Genetics, South Parks Road, Oxford, OX1 3QX, UK.

*Correspondence to: David Beeson, Email: dbeeson@hammer.imm.ox.ac.uk, Tel: +1865 222311, Fax: +1865 222402

© Copyright Amr Abdelgany et al

(Received 27 May 2005; Revised 07 July 2005; Accepted 08 July 2005)

 

Privacy | Disclaimer

©Library Publishing Media. All rights reserved.